Text Size
679 studies found for:    "Hypercholesterolemia"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: mipomersen sodium
2 Completed
Has Results 		Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: mipomersen sodium
3 Completed
Has Results 		Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Interventions: Drug: mipomersen;   Drug: Placebo
4 Terminated A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158 AM1)
Conditions: Hypercholesterolemia, Familial;   Heterozygous Familial Hypercholesterolemia
Intervention: Drug: MK-0524A
5 Completed Polish Survey on the Efficacy of the Hypercholesterolemia Treatment
Condition: Hypercholesterolemia
Intervention:
6 Completed A Study to Evaluate the Effects of MK0653 on the Postprandial (Following a Meal) Lipoprotein Response in Patients With Primary Hypercholesterolemia (High Cholesterol)
Condition: Hypercholesterolemia
Interventions: Drug: ezetimibe;   Drug: Comparator: placebo
7 Completed A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)(COMPLETED)
Conditions: Hypercholesterolemia;   Familial Hypercholesterolemia;   Homozygous Sitosterolemia
Interventions: Drug: Ezetimibe;   Drug: Ezetimibe + other lipid-lowering medication(s)
8 Completed A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)(COMPLETED)
Conditions: Hypercholesterolemia;   Familial Hypercholesterolemia;   Homozygous Sitosterolemia
Interventions: Drug: Ezetimibe;   Drug: Ezetimibe + other lipid-lowering medication(s)
9 Completed Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
10 Completed
Has Results 		Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)
Conditions: Primary Hypercholesterolemia;   Homozygous Familial Hypercholesterolemia
Intervention: Drug: Ezetimibe
11 Completed Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention: Drug: MD-0727
12 Withdrawn Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia
Conditions: Hypercholesterolemia;   Dyslipidemia
Interventions: Biological: Placebo;   Biological: 1 mg/kg every 2 weeks;   Biological: 2 mg/kg every 4 weeks;   Biological: 4 mg/kg every 4 weeks;   Biological: 4 mg/kg every 8 weeks;   Biological: 8 mg/kg every 8 weeks;   Biological: 12 mg/kg every 8 weeks
13 Completed Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
Conditions: Hypercholesterolemia;   Dyslipidemia
Intervention: Biological: PF-04950615 (RN316)
14 Completed Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia
Conditions: Hypercholesterolemia;   Cardiovascular Disease;   Hypertension;   Diabetes;   Coronary Heart Disease;   Peripheral Arterial Disease
Intervention:
15 Completed Pan-European Survey on the Under Treatment of Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
16 Completed Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
17 Completed
Has Results 		Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
Conditions: Hypercholesterolemia;   Dyslipidemia
Intervention: Drug: Pitavastatin
18 Completed Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
19 Completed An Epidemiological Study Aimed to Record Standard Daily Practice in Managing Patients With Hypercholesterolemia
Condition: Hypercholesterolemia
Intervention:
20 Completed Effect of the Plantago Ovata Husk on the Lipid Profile of Patients With Hypercholesterolemia
Conditions: Hypercholesterolemia;   Cardiovascular Disease
Intervention: Drug: Plantago ovata husk
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years